JONATHAN JAY MAZELSKY - 04 Dec 2023 Form 4 Insider Report for IDEXX LABORATORIES INC /DE (IDXX)

Role
President and CEO, Director
Signature
/s/ Lily J. Lu, Attorney-in-Fact for Jonathan Jay Mazelsky
Issuer symbol
IDXX
Transactions as of
04 Dec 2023
Net transactions value
-$2,589,304
Form type
4
Filing time
06 Dec 2023, 17:01:27 UTC
Previous filing
16 Oct 2023
Next filing
02 Jan 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IDXX Common Stock Options Exercise $1,067,745 +13,424 +18% $79.54* 86,361 04 Dec 2023 Direct F1
transaction IDXX Common Stock Sale $2,977,162 -5,804 -6.7% $512.95 80,557 04 Dec 2023 Direct F2
transaction IDXX Common Stock Sale $679,887 -1,324 -1.6% $513.51 79,233 04 Dec 2023 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IDXX Non-Qualified Stock Option (right-to-buy) Options Exercise -13,424 -100% 0 04 Dec 2023 Common Stock 13,424 $79.54 Direct F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 12 shares purchased under the Issuer's Employee Stock Purchase Plan on September 29, 2023.
F2 Represents the weighted average price of the shares sold ranging from a low of $512.35 to a high of $513.35 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F3 Represents the weighted average price of the shares sold ranging from a low of $513.36 to a high of $513.76 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F4 Grant of option to buy 13,424 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five annual installments beginning on February 14, 2016 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
F5 Not applicable.